"There continues to be an expensive use of bio-identical combination of hormone therapy as citied in recent publications with over 30 million prescriptions each year for a compounded bio identical estradiol and progesterone. The Drug Quality and Security Act and other forces have cut most, if not all, reimbursement for compounding drugs, and we believe this is affecting most compound in pharmacies. Assuming positive data and approval for estradiol and progesterone product candidate, we see these pharmacies as a strategic fit and partners for TherapeuticsMD. Our goal is to build a bridge that economically [in sense] non-sterile, retail pharmacies that currently compound estradiol and progesterone products to sell our product."